Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.4.21.77: semenogelase

This is an abbreviated version!
For detailed information about semenogelase, go to the full flat file.

Word Map on EC 3.4.21.77

Reaction

Preferential cleavage: -Tyr-/- =

Synonyms

7S nerve growth factor gamma chain, antigen (human clone lambdaHPSA-1 prostate-specific protein moiety reduced), antigen PSA (human clone 5P1 protein moiety reduced), antigen PSA (human prostate-specific), gama-SM protein, gamma-NGF, gamma-seminoglycoprotein (human protein moiety reduced), gamma-seminoprotein, gamma-SM, GK3, glandular kallikrein, glandular kallikrein 3, hK3/PSA, K3, K4, kallikrein 3, kallikrein-related peptidase 3, kallikrein-related peptidase-3, KLK3, P-30 antigen, prostate specific antigen, prostate stem cell antigen, prostate-specific antigen, prostate-specific antigen kallikrein, Prostate-specific membrane antigen, PSA, PSA-SV5, PSCA, PSMA, S01.162, seminal proteinase, seminin, six-transmembrane epithelial antigen of the prostate, STEAP, tissue kallikrein

ECTree

     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.21 Serine endopeptidases
                3.4.21.77 semenogelase

Expression

Expression on EC 3.4.21.77 - semenogelase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
at a dose of 0.00001 mM 17-allylamine-17-demethoxygeldanamycin, PSA expression is reduced by 40%. 17-allylamine-17-demethoxygeldanamycin-treated LNCaP cells reveal about 25% inhibition of PSA secretion. Potency of AUY922 to reduce PSA expression at inhibitor concentrations lower than 0.000005 mM (non-toxic at these levels) is greater (8fold) than the potency of 17-allylamine-17-demethoxygeldanamycin. Hsp90 inhibitors target PSA secretion via the androgen receptor pathway
-
inactive proenzyme is produced at high concentrations by epithelial cells of the prostate
-
LNCaP and 22RV1 xenograft tumors express PSA
-
PSA expression is lower in malignant than in normal prostatic epithelium and it is further reduced in poorly differentiated tumors
-
PSA-specific monoclonal antibodies block proteolysis of extracellular matrix components and decrease invasion of PSA-producing LNCaP cells in Matrigel invasion assays
-
shRNA mediated knockdown of SNF2-related CBP activator protein results in decreased H2A.Z binding at the enhancer region of the PSA promoter and decreased expression of PSA in prostate cancer cells
-
SNF2-related CBP activator protein is a physiologically relevant mediator of PSA expression: it enhances the transcriptional activity of PSA and this activation is further enhanced in the presence of dihydrotestosterone. SNF2-related CBP activator protein activates hormone-dependent transcription of the androgen responsive, PSA-Luciferase reporter gene in prostate cells
-
treatment of LNCaP cells with 10 microg/ml soy isoflavones alone causes 40% inhibition of PSA secretion to the supernatant compared to control, whereas treatment of the cells with 20 micromol curcumin causes 20% inhibition. Combined treatment of curcumin and soy isoflavones enhances inhibition of PSA production and expression of androgen receptor in LNCaP cells: treatment with 10 microg/ml isoflavones combined with 20 micromol curcumin causes almost complete inhibition of PSA production. In a randomized, placebo-controlled clinical trial, a combined treatment of soy isoflavones and curcumin decreases serum PSA in those subjects whose baseline PSA is more than 10 ng/ml
-